Medication classes
Immunomodulator articles covering azathioprine, mercaptopurine, methotrexate, safety monitoring, and combination therapy in IBD. Medication context emphasizes treatment decisions, safety, approvals, and therapy access.
Page 2 of 2 · 64 articles
Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.
This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...
This case report describes successful use of vedolizumab to treat severe UC in a patient who also had PSC and SLE — a rare and complex combination. Patients and clinicians may find it relevant when considering biologic...
The FDA label for XELJANZ/XELJANZ XR (tofacitinib) highlights serious safety risks and monitoring steps relevant to people with ulcerative colitis and other autoimmune conditions who may be using or considering this JAK...
People with IBD who also have bleeding disorders face special risks during endoscopy, surgery, and when using immunosuppressive drugs. This case shows that coordinated care and hemostatic support can allow diagnosis and...
The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Fatigue affects a large majority of pediatric IBD patients and is linked to worse quality of life even when disease is in remission, so it’s a common problem families and clinicians will likely encounter. Understanding...
This is a patient-friendly summary explaining what Crohn’s disease is, common symptoms, and typical treatment and monitoring approaches. It can help people recognize symptoms and understand basic management options.
Market reports can signal which drugs, companies, and biosimilars are becoming more available and may affect access and cost. Announcements about biosimilars could influence treatment affordability and prescribing...
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
This study suggests a common genetic marker (HLA‑DQA1*05) may help explain why some children stop responding to anti‑TNF drugs and could eventually guide who might benefit from adding methotrexate or closer monitoring.
This article is a market research summary about the global Crohn’s disease treatment market — it describes sales forecasts, industry players, and market trends rather than new clinical findings or patient-focused...
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
